Bitolterol

Clinical data
Trade names	Tornalate
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601236
ATC code	R03AC17 (WHO)
Legal status
Legal status	US: Discontinued
Pharmacokinetic data
Onset of action	2–5 minutes
Duration of action	6–8 hours
Identifiers
IUPAC name (RS)-[4-(1-Hydroxy-2-tert-butylamino-ethyl)-2-(4-methylbenzoyl)oxy-phenyl] 4-methylbenzoate
CAS Number	30392-40-6 mesylate: 30392-41-7 Y
PubChem CID	35330
DrugBank	DB00901
ChemSpider	32525
UNII	9KY0QXD6LI mesylate: 4E53T3611U Y
KEGG	D07534 Y mesylate: D00684 Y
ChEMBL	ChEMBL1201295 Y
CompTox Dashboard (EPA)	DTXSID1022683
Chemical and physical data
Formula	C28H31NO5
Molar mass	461.558 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES O=C(Oc2cc(ccc2OC(=O)c1ccc(cc1)C)C(O)CNC(C)(C)C)c3ccc(cc3)C

Bitolterol mesylate, formerly sold under the brand name Tornalate, is a short-acting β₂-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma^[1][2] and chronic obstructive pulmonary disease (COPD).^[3][4][5] Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them.

Bitolterol is a prodrug of colterol.^[6][7] It has a rapid onset of action (2–5 minutes) and may last up to 6–8 hours.^[8] The drug, alone or in co-administration with theophylline, doesn't show cardiotoxic effect.^[9]

The US Food and Drug Administration (FDA) approved bitolterol in December 1984. The drug was withdrawn from the market by Élan Pharmaceuticals in 2001.

1. ^ Nathan RA, Bodman SF, Storms WW, Mingo TS (June 1986). "Bitolterol mesylate aerosol in adults with steroid-dependent asthma: a comparison with isoproterenol hydrochloride aerosol". Annals of Allergy. 56 (6): 494–499. PMID 3717716.
2. ^ Nathan RA, Bernstein IL, Bronsky EA, Bush RK, Chervinsky P, Condemi JJ, et al. (May 1987). "Comparison of the bronchodilator effects of nebulized bitolterol mesylate and isoproterenol hydrochloride in steroid-dependent asthma". The Journal of Allergy and Clinical Immunology. 79 (5): 822–829. doi:10.1016/0091-6749(87)90216-8. PMID 3571773.
3. ^ Friedel HA, Brogden RN (January 1988). "Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease". Drugs. 35 (1): 22–41. doi:10.2165/00003495-198835010-00002. PMID 3278878. S2CID 218471864. Archived from the original on 2012-12-23.
4. ^ "Early Career Awards for 1978 (John Robert Anderson, Philip M. Groves, Gary E. Schwartz)". The American Psychologist. 34 (1): 69–79. January 1979. doi:10.1037/h0078247. PMID 396832.
5. ^ Petty TL, Scoggin CH, Rollins DR, Repsher LH (September 1984). "Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease". Chest. 86 (3): 404–408. doi:10.1378/chest.86.3.404. PMID 6380974.
6. ^ Walker SB, Kradjan WA, Bierman CW (6 May 1985). "Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma". Pharmacotherapy. 5 (3): 127–137. doi:10.1002/j.1875-9114.1985.tb03410.x. PMID 3895171. S2CID 29431526.
7. ^ "ChEBI: Bitolterol". Chemical Entities of Biological Interest. Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK. Retrieved 27 March 2016.
8. ^ Kass I, Mingo TS (August 1980). "Bitolterol mesylate (WIN 32784) aerosol. A new long-acting bronchodilator with reduced chronotropic effects". Chest. 78 (2): 283–287. doi:10.1378/chest.78.2.283. PMID 6995040.
9. ^ Kemp JP, Chervinsky P, Orgel HA, Meltzer EO, Noyes JH, Mingo TS (January 1984). "Concomitant bitolterol mesylate aerosol and theophylline for asthma therapy, with 24 hr electrocardiographic monitoring". The Journal of Allergy and Clinical Immunology. 73 (1 Pt 1): 32–43. doi:10.1016/0091-6749(84)90481-0. PMID 6693665.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

• v
• t
• e